Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · Jan 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ZG005, which is being tested together with standard chemotherapy drugs (Paclitaxel and Platinum-based drugs) and possibly another drug called Bevacizumab. The goal is to find out if this combination is effective for women with advanced cervical cancer, a type of cancer that starts in the cervix. The trial is currently looking for female participants between the ages of 18 and 70 who are able to understand the study and can commit to being part of it.

To take part in this study, participants should be in good overall health, meaning they can perform daily activities and are expected to live for at least three more months. Those who do not meet the health criteria set by the doctors will not be included. If someone joins the trial, they will be closely monitored to see how well the treatment works and to check for any side effects. This study is an important step in finding new options for women facing advanced cervical cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Fully understand the study and voluntarily sign the informed consent form.
• • Female 18-70 years of age;
• • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
• • Life expectancy ≥ 3 months.
• Exclusion Criteria:
• • Patients were deemed unsuitable for participating in the study by the investigator for any reasons.